Cargando…
The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity
Immune thrombocytopenia (ITP) treatment has evolved recently. However, none of the treatments have only benefits without drawbacks. This study aimed to compare the clinical outcomes and adverse drug patterns of Eltrombopag, Romiplostim, Prednisolone + Azathioprine, High Dose-dexamethasone (HD-DXM) (...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303883/ https://www.ncbi.nlm.nih.gov/pubmed/37375815 http://dx.doi.org/10.3390/ph16060868 |
_version_ | 1785065380355506176 |
---|---|
author | Hamed, Eman Mostafa Ibrahim, Ahmed R. N. Meabed, Mohamed Hussein Khalaf, Ahmed M. El Demerdash, Doaa Mohamed Elgendy, Marwa O. Saeed, Haitham Salem, Heba F. Rabea, Hoda |
author_facet | Hamed, Eman Mostafa Ibrahim, Ahmed R. N. Meabed, Mohamed Hussein Khalaf, Ahmed M. El Demerdash, Doaa Mohamed Elgendy, Marwa O. Saeed, Haitham Salem, Heba F. Rabea, Hoda |
author_sort | Hamed, Eman Mostafa |
collection | PubMed |
description | Immune thrombocytopenia (ITP) treatment has evolved recently. However, none of the treatments have only benefits without drawbacks. This study aimed to compare the clinical outcomes and adverse drug patterns of Eltrombopag, Romiplostim, Prednisolone + Azathioprine, High Dose-dexamethasone (HD-DXM) (control group), and Rituximab in primary ITP Egyptian patients. All patients were initiated with corticosteroids, HD-DXM, as a first-line treatment for the first month immediately following diagnosis. Four hundred sixty-seven ITP patients were randomly assigned to five groups. The outcome measures were judged at baseline, at the end of treatment (6 months), and after an additional 6-month free treatment period. The follow-up period for which relapse is noted was 6 months after the end of treatment. Eltrombopag and Romiplostim resulted in a significantly higher incidence of sustained response than Rituximab, HD-DXM, and Prednisolone + Azathioprine (55.2% and 50.6% vs. 29.2%, 29.1%, and 18%, respectively; p-value < 0.001). More patients on immunomodulators (Prednisolone+ Azathioprine, HD-DXM, and Rituximab) relapsed than those on Romiplostim and Eltrombopag (81.9%, 70.8%, and 70.7% vs. 49.3%, and 44.7%, respectively; p-value < 0.01). We also describe 23 reports of pulmonary hypertension with Prednisolone+ Azathioprine and 13 reports with HD-DXM. The thrombotic events occurred in 16.6% and 13% of patients who received Eltrombopag and Romiplostim treatment, respectively. Most patients had at least one or two risk factors (92.8% of cases). Corticosteroids are effective first-line therapy in primary ITP patients. However, relapse is frequent. Eltrombopag and Romiplostim are safer and more effective than Prednisolone, HD-DXM, and Rituximab. They might be reasonable beneficial options after a one-month HD-DXM regimen. |
format | Online Article Text |
id | pubmed-10303883 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103038832023-06-29 The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity Hamed, Eman Mostafa Ibrahim, Ahmed R. N. Meabed, Mohamed Hussein Khalaf, Ahmed M. El Demerdash, Doaa Mohamed Elgendy, Marwa O. Saeed, Haitham Salem, Heba F. Rabea, Hoda Pharmaceuticals (Basel) Article Immune thrombocytopenia (ITP) treatment has evolved recently. However, none of the treatments have only benefits without drawbacks. This study aimed to compare the clinical outcomes and adverse drug patterns of Eltrombopag, Romiplostim, Prednisolone + Azathioprine, High Dose-dexamethasone (HD-DXM) (control group), and Rituximab in primary ITP Egyptian patients. All patients were initiated with corticosteroids, HD-DXM, as a first-line treatment for the first month immediately following diagnosis. Four hundred sixty-seven ITP patients were randomly assigned to five groups. The outcome measures were judged at baseline, at the end of treatment (6 months), and after an additional 6-month free treatment period. The follow-up period for which relapse is noted was 6 months after the end of treatment. Eltrombopag and Romiplostim resulted in a significantly higher incidence of sustained response than Rituximab, HD-DXM, and Prednisolone + Azathioprine (55.2% and 50.6% vs. 29.2%, 29.1%, and 18%, respectively; p-value < 0.001). More patients on immunomodulators (Prednisolone+ Azathioprine, HD-DXM, and Rituximab) relapsed than those on Romiplostim and Eltrombopag (81.9%, 70.8%, and 70.7% vs. 49.3%, and 44.7%, respectively; p-value < 0.01). We also describe 23 reports of pulmonary hypertension with Prednisolone+ Azathioprine and 13 reports with HD-DXM. The thrombotic events occurred in 16.6% and 13% of patients who received Eltrombopag and Romiplostim treatment, respectively. Most patients had at least one or two risk factors (92.8% of cases). Corticosteroids are effective first-line therapy in primary ITP patients. However, relapse is frequent. Eltrombopag and Romiplostim are safer and more effective than Prednisolone, HD-DXM, and Rituximab. They might be reasonable beneficial options after a one-month HD-DXM regimen. MDPI 2023-06-12 /pmc/articles/PMC10303883/ /pubmed/37375815 http://dx.doi.org/10.3390/ph16060868 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hamed, Eman Mostafa Ibrahim, Ahmed R. N. Meabed, Mohamed Hussein Khalaf, Ahmed M. El Demerdash, Doaa Mohamed Elgendy, Marwa O. Saeed, Haitham Salem, Heba F. Rabea, Hoda The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity |
title | The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity |
title_full | The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity |
title_fullStr | The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity |
title_full_unstemmed | The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity |
title_short | The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity |
title_sort | outcomes and adverse drug patterns of immunomodulators and thrombopoietin receptor agonists in primary immune thrombocytopenia egyptian patients with hemorrhage comorbidity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303883/ https://www.ncbi.nlm.nih.gov/pubmed/37375815 http://dx.doi.org/10.3390/ph16060868 |
work_keys_str_mv | AT hamedemanmostafa theoutcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT ibrahimahmedrn theoutcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT meabedmohamedhussein theoutcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT khalafahmedm theoutcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT eldemerdashdoaamohamed theoutcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT elgendymarwao theoutcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT saeedhaitham theoutcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT salemhebaf theoutcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT rabeahoda theoutcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT hamedemanmostafa outcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT ibrahimahmedrn outcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT meabedmohamedhussein outcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT khalafahmedm outcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT eldemerdashdoaamohamed outcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT elgendymarwao outcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT saeedhaitham outcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT salemhebaf outcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity AT rabeahoda outcomesandadversedrugpatternsofimmunomodulatorsandthrombopoietinreceptoragonistsinprimaryimmunethrombocytopeniaegyptianpatientswithhemorrhagecomorbidity |